Advertisement


Martin Reck, MD, PhD, on NSCLC: Pembrolizumab, Platinum Chemotherapy, and Radiotherapy in Advanced Disease

IASLC 2020 World Conference on Lung Cancer in Singapore

Advertisement

Martin Reck, MD, PhD, of the LungenClinic, discusses the results from KEYNOTE-799, which explored a new strategy to increase the intensity of treatment in patients with unresectable, locally advanced, stage III non–small cell lung cancer (Abstract OA02.03).



Related Videos

Lung Cancer
Immunotherapy

Martin Reck, MD, PhD, on SCLC: Maintenance Therapy for Patients With Extensive-Stage Disease

Martin Reck, MD, PhD, of LungenClinic, discusses results from the IMpower133 study of carboplatin plus etoposide with or without atezolizumab in patients with untreated extensive-stage small cell lung cancer (Abstract OA11.06).

Lung Cancer
Immunotherapy

Martin Reck, MD, PhD, on NSCLC: Pembrolizumab Plus Ipilimumab in First-Line Treatment

Martin Reck, MD, PhD, of the LungenClinic, discusses findings of the KEYNOTE-598 study, which showed that pembrolizumab plus ipilimumab was more toxic and offered no more benefit in terms of efficacy than pembrolizumab plus placebo in first-line therapy for patients with metastatic high PD-L1–expressing non–small cell lung cancer (Abstract PS01.09).

Lung Cancer

Silvia Novello, MD, PhD, on NSCLC: Pharmacogenomics-Driven vs Standard Adjuvant Chemotherapy

Silvia Novello, MD, PhD, of the University of Turin, discusses phase III results from the ITACA trial, which explored the notion of improving survival by customizing treatment and reducing toxicities for patients with completely resected stage II to IIIA non–small cell lung cancer (Abstract PS01.04).

Lung Cancer

Roy S. Herbst, MD, PhD, on NSCLC: Osimertinib and Patient-Reported Outcomes

Roy S. Herbst, MD, PhD, of Yale University, discusses two key abstracts from the ADAURA trial: the use of osimertinib as adjuvant therapy for resected EGFR-mutated non–small cell lung cancer; and patient-reported outcomes, which showed a benefit in disease-free survival and maintenance of health-related quality of life in patients with resected stage IB to IIIA disease (Abstracts OA06.04 and OA06.03).

Lung Cancer

Luis M. Montuenga, PhD, on Noninvasive Biomarkers in Lung Cancer Screening

Luis M. Montuenga, PhD, of the University of Navarra, discusses the potential contributions of biomarkers, promising biomarker panels being tested and published, the need to standardize biospecimen collection, and how to improve the sensitivity of these biomarkers (Abstract PL05.06).

Advertisement

Advertisement



Advertisement